Real-World Outcomes of Heavily Pretreated Relapsed Refractory Multiple Myeloma Patients Treated with Bispecific Antibodies

Key Points

• Treatment outcomes in multiple myeloma show significant improvement with bispecific antibodies, especially among heavily pretreated patients.
• Overall response rates reached 75% in this population receiving bispecific antibody therapy.
• This analysis highlights efficacy through patient records from various healthcare settings with a focus on real-world data.
• Using bispecific antibodies demonstrates a promising avenue for therapy in challenging multiple myeloma cases requiring new approaches.